Microencapsulated Octreotide Pamoate in Advanced Cancer
Author Information
Author(s): Si Hellel, J Geisler, JP Poulsen, K Hestdal, K Meadows, W Collins, KM Tveit, A Vistes, JMP Holly, PE Lonning
Primary Institution: Haukeland University Hospital
Hypothesis
Can microencapsulated octreotide pamoate improve treatment outcomes in patients with advanced gastrointestinal and pancreatic cancer?
Conclusion
Microencapsulated octreotide is well tolerated and significantly affects several components of the IGF system in plasma.
Supporting Evidence
- Two patients had stable disease for 4 and 6 months.
- Plasma IGF-I decreased by 49-53% and IGF-II by 27-37%.
- Insulin and C-peptide levels decreased by 29-38% and 41-46%, respectively.
Takeaway
This study tested a new medicine on 14 patients with serious cancer, and it seemed to help their bodies in some ways without causing bad side effects.
Methodology
Patients received different doses of microencapsulated octreotide pamoate, and their blood was tested for various hormone levels over time.
Limitations
The study had a small sample size and was limited to specific cancer types.
Participant Demographics
Median age was 64 years, with 8 men and 6 women.
Statistical Information
P-Value
p<0.05
Confidence Interval
95%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website